This Week in Nephrology — Jun 20, 2026

Welcome to This Week in Nephrology. This week we are covering nine notable papers spanning clinical management strategies in vulnerable kidney populations, precision medicine and individualized care, and translational breakthroughs in imaging, genetics, and transplant tolerance. Let us dive in. We begin with clinical management strategies in vulnerable patient populations, where recent studies challenge traditional practice patterns and highlight hidden risks. First, we examine the impact of iodinated contrast media on patients who have recently recovered from dialysis-requiring acute kidney injury. Even when these patients appear to have recovered and have successfully discontinued dialysis, their kidneys may remain highly vulnerable to subsequent insults. In a target trial emulation study published in the American Journal of Kidney Diseases, researchers used Taiwan's National Health Insurance Research Database to evaluate over twenty-three thousand adults who recovered from dialysis-requiring acute kidney injury [1]. Within this cohort, about seven percent received contrast-enhanced computed tomography within thirty days of stopping dialysis. Using inverse probability of treatment weighting, the investigators found that contrast exposure was independently associated with a thirty-seven percent higher hazard of needing to restart dialysis, and an eleven percent higher hazard of developing persistent kidney dysfunction, which was defined as a fifty percent or greater increase in serum creatinine. Interestingly, generalized additive modeling revealed that the risk of these adverse kidney events was highest when the post-recovery estimated glomerular filtration rate fell below thirty-six milliliters per minute per one point seven three square meters in patients who received contrast, compared to a threshold of about twenty-three milliliters per minute in those who did not. These findings, which were confirmed in an independent validation cohort of nearly twelve hundred patients, suggest that we must exercise extreme caution and carefully weigh risks and benefits when ordering contrast-enhanced studies in patients who have recently transitioned off dialysis. Moving from acute kidney injury recovery to end-stage kidney disease, a pilot randomized trial published in the Journal of the American Society of Nephrology challenges the dogmatic prioritization of arteriovenous fistulas over central venous catheters in older adults starting hemodialysis [2]. The ACCESS HD trial, conducted across twelve centers in Canada and Australia, randomized patients aged fifty-five and older who started hemodialysis using a central venous catheter to either an attempt at arteriovenous fistula creation or the continued use of a tunneled central venous catheter. Out of nearly thirteen hundred patients screened, only sixty-seven underwent randomization. The primary barrier to recruitment was strong patient preference, as only twenty-five percent of eligible patients agreed to be randomized, with the majority preferring to continue dialyzing with their catheter. Among those randomized to the fistula group, seventy-one percent underwent placement within ninety days. Interestingly, patients randomized to the fistula strategy experienced nominally more access-related interventions, hospitalizations, and bacteremia, the majority of which were catheter-related during the bridging period, while the catheter group experienced a greater reliance on thrombolytic therapy. Ultimately, this pilot trial suggests that a definitive randomized trial of fistulas versus catheters is not feasible in the current clinical climate due to strong patient preferences. It also provides reassurance that there was no signal of excess harm associated with the catheter-only strategy, suggesting that clinicians should carefully consider patient preferences and individual clinical profiles rather than strictly adhering to a fistula-first approach in older adults. Next, we look at how we manage frail older adults with chronic kidney disease. These patients often have complex care needs that might benefit from a comprehensive geriatric assessment, but the optimal delivery model remains unclear. In the GOAL trial, published in Kidney International, researchers conducted an open-label, cluster-randomized controlled trial across fifteen Australian outpatient centers to evaluate whether a one-off outpatient comprehensive geriatric assessment, paired with an individualized management plan, could improve patient-centered goal attainment [4]. They screened over seven hundred patients and enrolled two hundred and forty individuals with a mean age of nearly seventy-seven years and moderate to severe chronic kidney disease. At three months, there was no statistically significant difference in Goal Attainment Scaling scores between the intervention and control groups, with scores of forty-five point two and forty-three point seven, respectively. There were also no significant differences in secondary outcomes such as quality of life, frailty status, mortality, or hospitalizations, though a non-statistically significant reduction of two and a half days in total hospital stay was noted in the intervention group. These findings indicate that a single-episode outpatient comprehensive geriatric assessment does not improve outcomes, suggesting a need for alternative, integrated, and continuous models of person-centered care for our frail patients rather than one-time interventions. Our second theme focuses on precision medicine and individualized care, highlighted by new insights into gender-affirming hormone therapy and standardized guidelines for pediatric transplantation. First, a longitudinal cohort study published in the Clinical Journal of the American Society of Nephrology examined how gender-affirming hormone therapy affects kidney function trajectories in transgender and gender diverse veterans [5]. Using United States Veterans Health Administration data from 2006 to 2019, researchers analyzed over six thousand cisgender controls and two hundred and sixty-two transgender veterans, including two hundred and fourteen transgender women and forty-eight transgender men. The investigators found that transgender men receiving testosterone therapy experienced higher serum creatinine levels as early as three months after starting treatment, which stabilized by twelve months, leading to a significantly lower estimated glomerular filtration rate. In contrast, transgender women receiving estrogen did not show any significant changes in serum creatinine or estimated glomerular filtration rate. These divergent paths highlight the profound impact of hormone-induced changes in muscle mass on creatinine-based kidney function estimates. For clinicians, this underscores the critical need for individualized kidney monitoring and potentially refined estimated glomerular filtration rate calculations that account for both affirmed gender and sex assigned at birth in transgender populations. Moving to pediatric populations, the need for individualized, evidence-based care is equally pressing. Pediatric kidney transplantation often suffers from a lack of robust clinical trial evidence, leading to highly variable practice patterns globally. To address this, a consortium of European and German medical societies developed an evidence- and consensus-based guideline for immunosuppressive therapy in children and adolescents after kidney transplantation, published in the journal Transplantation [8]. Developed between January 2024 and December 2025, the guideline provides standardized, up-to-date recommendations that advocate for individualized immunosuppression, including the integration of newer agents. By establishing formal consensus in areas where clinical evidence is weak or relies on expert opinion, this guideline aims to reduce practice variability and ultimately improve long-term patient and allograft survival in pediatric recipients. Our third theme dives into translational science, where researchers are pushing the boundaries of diagnostics, genetic mechanisms, and transplant tolerance. On the diagnostic front, a study published in Kidney International evaluated near-infrared autofluorescence imaging as a non-invasive tool to assess tubular epithelial cell injury without using any external contrast agents or probes [3]. Tubulointerstitial fibrosis is the final common pathway to kidney failure, but tracking tubular epithelial cell injury in real-time has historically required invasive biopsies. Testing this technology in three distinct mouse models of kidney injury, the researchers found that near-infrared autofluorescence strongly correlated with tubular epithelial cell injury, oxidative stress markers, and fibrosis. They identified coproporphyrin III, a metabolite in the heme biosynthesis pathway, as the primary fluorophore accumulating in damaged cells due to a reduction in the enzyme coproporphyrinogen oxidase. To validate its utility in monitoring treatment, they administered the mineralocorticoid receptor antagonist finerenone to injured mice, which led to a reduction in autofluorescence that mirrored histological improvement. Crucially, the researchers also examined thirty-four human kidney samples ex vivo, finding that autofluorescence correlated inversely with estimated glomerular filtration rate and positively with tissue injury scores. This technology provides a potential pathway for non-invasive, real-time longitudinal monitoring of kidney disease progression and therapeutic responses in clinical settings. While imaging helps us see cell injury, understanding the intracellular pathways that drive podocyte death is key to developing new therapies, particularly for genetically vulnerable populations. Individuals of African ancestry carrying the G1 or G2 risk variants of the APOL1 gene have a significantly higher risk of chronic kidney disease, but this requires a secondary stressor like hypoxia or inflammation to trigger podocyte injury. In a study published in Kidney International, researchers conducted a genome-wide RNA interference screen in cells expressing these APOL1 variants under hypoxic stress and identified several peroxisomal biogenesis, or PEX, genes as critical modifiers of cell survival [7]. Silencing these PEX genes significantly worsened cell death, whereas enhancing peroxisomal function, either genetically or pharmacologically, protected the cells. The investigators discovered that APOL1 contains a functional peroxisomal targeting signal at its C-terminus that drives its trafficking to peroxisomes during hypoxia. Disruption of this signal reduced peroxisomal localization and mitigated the toxic effects of the G1 and G2 variants. This study establishes a direct mechanistic link between hypoxia, peroxisomal homeostasis, and APOL1-induced podocytopathy, pointing to peroxisomes as a promising therapeutic target to limit podocyte injury and chronic kidney disease progression. Moving from cellular mechanisms to clinical applications in transplantation, researchers have made a significant breakthrough in inducing transplant tolerance. Achieving donor chimerism through bone marrow cotransplantation has long been a goal in kidney transplantation to eliminate the need for lifelong immunosuppression, but historical protocols required toxic recipient irradiation. In a phase one slash two-a controlled trial published in Science Translational Medicine, researchers evaluated a combination therapy of polyclonal recipient regulatory T cells and donor bone marrow cells administered immediately after human leukocyte antigen-mismatched living-donor kidney transplantation [9]. Six patients in the study group received this cell therapy alongside an immunosuppressive regimen of thymoglobulin, belatacept, sirolimus, steroids, and a short course of tocilizumab, while the control group did not receive the cell therapy. The primary endpoint was met, as all patients in the study group achieved donor leukocyte chimerism across multiple lineages, with up to four percent chimerism in T cells, whereas no chimerism was detected in the control group. Furthermore, three patients in the study group successfully minimized their immunosuppression to belatacept monotherapy, and in vitro assays showed decreased antidonor reactivity. This trial provides a critical proof of concept that combining regulatory T cells with donor bone marrow can safely induce donor chimerism and immunomodulation without the need for toxic irradiation. Finally, we look to the horizon of clinical practice with a study from Nature exploring the integration of medical artificial intelligence into daily workflows [6]. While large language models have shown promise in isolated medical tasks, they are typically limited to standalone chat interfaces. In this study, researchers introduced MIRA, which stands for Medical Intelligence for Reasoning and Action. MIRA is an autonomous artificial intelligence agent designed to operate within a sandboxed electronic health record environment with governed access to patient data. In simulations using real clinical cases with multiple diagnoses, MIRA was capable of navigating complex clinical actions, including gathering patient histories, ordering and interpreting laboratory and imaging tests, generating differential diagnoses, prescribing medications, and planning hospital admissions. Remarkably, MIRA outperformed physicians in diagnostic accuracy and made decisions that were highly guideline-concordant, medication-safe, and clinically appropriate. While prospective, real-world studies are still required to establish safety, generalizability, and governance, this work demonstrates that an electronic health record-integrated artificial intelligence agent can translate clinical intent into structured, actionable operations, offering a glimpse into the future of physician decision support. If you only have time for one paper this week, make it the target trial emulation study on contrast exposure after dialysis-requiring acute kidney injury published in the American Journal of Kidney Diseases [1]. This paper provides critical, real-world evidence that patients who have recently recovered from dialysis-requiring acute kidney injury remain highly vulnerable to recurrent injury, and it establishes clear, clinically actionable estimated glomerular filtration rate thresholds to help us safely manage contrast administration in this high-risk population. Here are the key takeaways from this week in Nephrology. First, patients who have recently recovered from dialysis-requiring acute kidney injury face a significantly higher risk of returning to dialysis and developing persistent kidney dysfunction if exposed to iodinated contrast within thirty days of recovery, particularly if their estimated glomerular filtration rate is below thirty-six milliliters per minute. Second, the pilot ACCESS HD trial suggests that dogmatic adherence to a fistula-first strategy in older adults starting hemodialysis may not be necessary or feasible, as patients have strong preferences for keeping central venous catheters, and the catheter-only approach did not show an increased signal of harm. Third, gender-affirming hormone therapy has divergent effects on kidney function estimates, with transgender men experiencing a rapid rise in serum creatinine and a corresponding drop in estimated glomerular filtration rate within three months of starting testosterone, highlighting the need for individualized monitoring. Fourth, combining recipient regulatory T cells with donor bone marrow cells immediately after kidney transplantation can successfully induce donor chimerism without recipient irradiation, representing a major step toward safer transplant tolerance. And finally, a single-episode outpatient comprehensive geriatric assessment does not improve goal attainment or clinical outcomes in frail older adults with chronic kidney disease, indicating that we must transition to more integrated, continuous care models. That's your roundup for This Week in Nephrology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.